These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 16531261)

  • 21. Intravenous busulfan and melphalan, tacrolimus, and short-course methotrexate followed by unmodified HLA-matched related or unrelated hematopoietic stem cell transplantation for the treatment of advanced hematologic malignancies.
    Small TN; Young JW; Castro-Malaspina H; Prockop S; Wilton A; Heller G; Boulad F; Chiu M; Hsu K; Jakubowski A; Kernan NA; Perales MA; O'Reilly RJ; Papadopoulos EB
    Biol Blood Marrow Transplant; 2007 Feb; 13(2):235-44. PubMed ID: 17241929
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term follow-up of allogeneic hematopoietic stem cell transplantation for de novo acute myelogenous leukemia with a conditioning regimen of total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine.
    Mori T; Aisa Y; Watanabe R; Yamazaki R; Kato J; Shimizu T; Shigematsu N; Kubo A; Yajima T; Hibi T; Ikeda Y; Okamoto S
    Biol Blood Marrow Transplant; 2008 Jun; 14(6):651-7. PubMed ID: 18489990
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic variables in bone marrow transplantation for secondary leukaemia and myelodysplastic syndromes: a survey of the working party on leukaemia.
    de Witte T; Hermans J; van Biezen A; Vernant J; Kolb H; Zwaan F; Vossen J; Lönnqvist B; Beelen D; Ferrant A
    Bone Marrow Transplant; 1991; 7 Suppl 2():40. PubMed ID: 1878713
    [No Abstract]   [Full Text] [Related]  

  • 24. Disease burden may identify patients more likely to benefit from second allogeneic hematopoietic stem cell transplantation to treat relapsed acute myelogenous leukemia.
    Hosing C; Saliba RM; Shahjahan M; Estey EH; Couriel D; Giralt S; Andersson B; Champlin RE; De Lima M
    Bone Marrow Transplant; 2005 Jul; 36(2):157-62. PubMed ID: 15937511
    [TBL] [Abstract][Full Text] [Related]  

  • 25. IPSS poor-risk karyotype as a predictor of outcome for patients with myelodysplastic syndrome following myeloablative stem cell transplantation.
    Nevill TJ; Shepherd JD; Sutherland HJ; Abou Mourad YR; Lavoie JC; Barnett MJ; Nantel SH; Toze CL; Hogge DE; Forrest DL; Song KW; Power MM; Nitta JY; Dai Y; Smith CA
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):205-13. PubMed ID: 19167680
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic relevance of achieving cytogenetic remission in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome following induction chemotherapy.
    Balleisen S; Kuendgen A; Hildebrandt B; Haas R; Germing U
    Leuk Res; 2009 Sep; 33(9):1189-93. PubMed ID: 19428106
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hematopoietic stem cell transplantation after reduced intensity conditioning in acute myelogenous leukemia patients older than 40 years.
    Huisman C; Meijer E; Petersen EJ; Lokhorst HM; Verdonck LF
    Biol Blood Marrow Transplant; 2008 Feb; 14(2):181-6. PubMed ID: 18215778
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcomes of patients who undergo aggressive induction therapy for secondary acute myeloid leukemia.
    Rizzieri DA; O'Brien JA; Broadwater G; Decastro CM; Dev P; Diehl L; Beaven A; Lagoo A; Gockerman JP; Chao NJ; Moore JO
    Cancer; 2009 Jul; 115(13):2922-9. PubMed ID: 19452542
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term remissions in patients with myelodysplastic syndrome and secondary acute myelogenous leukemia undergoing allogeneic transplantation following a reduced intensity conditioning regimen of 550 cGy total body irradiation and cyclophosphamide.
    Hallemeier CL; Girgis MD; Blum WG; Brown RA; Khoury HJ; Devine SM; Vij R; Lin HS; DiPersio JF; Adkins DR
    Biol Blood Marrow Transplant; 2006 Jul; 12(7):749-57. PubMed ID: 16785064
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
    Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term outcomes of de novo acute myeloid leukemia in Thai patients.
    Niparuck P; Chuncharunee S; Ungkanont A; Udomtrupayakul U; Aungchaisuksiri P; Rerkamnuatchoke B; Jootar S; Atichartakarn V
    J Med Assoc Thai; 2009 Sep; 92(9):1143-9. PubMed ID: 19772172
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome.
    Sill H; Zinke-Cerwenka W; Berghold A
    Bone Marrow Transplant; 2007 Apr; 39(8):509; author reply 509-10. PubMed ID: 17322936
    [No Abstract]   [Full Text] [Related]  

  • 33. Comparable non-relapse mortality and survival after HLA-identical sibling blood stem cell transplantation with reduced or conventional-intensity preparative regimens for high-risk myelodysplasia or acute myeloid leukemia in first remission.
    Martino R; Valcárcel D; Brunet S; Sureda A; Sierra J
    Bone Marrow Transplant; 2008 Jan; 41(1):33-8. PubMed ID: 17982504
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Comparison of the effectiveness of chemotherapy and autologous hematopoietic stem cell transplantation as postremission treatment for adult acute lymphoblastic leukemia patients].
    Jin FY; Zou DH; Wang GR; Xu Y; Feng SZ; Zhao YZ; Han MZ; Yan WW; Qiu LG
    Zhonghua Xue Ye Xue Za Zhi; 2005 Nov; 26(11):645-8. PubMed ID: 16620547
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Unrelated donor bone marrow transplantation using a chemotherapy-only preparative regimen for adults with high-risk acute myelogenous leukemia.
    Ayash LJ; Ratanatharathorn V; Braun T; Silver SM; Reynolds CM; Uberti JP
    Am J Hematol; 2007 Jan; 82(1):6-14. PubMed ID: 16986128
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relative survival of long-term hematopoietic cell transplant recipients approaches general population rates.
    Nivison-Smith I; Simpson JM; Dodds AJ; Ma DD; Szer J; Bradstock KF
    Biol Blood Marrow Transplant; 2009 Oct; 15(10):1323-30. PubMed ID: 19747641
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia.
    Candoni A; Tiribelli M; Toffoletti E; Cilloni D; Chiarvesio A; Michelutti A; Simeone E; Pipan C; Saglio G; Fanin R
    Eur J Haematol; 2009 Jan; 82(1):61-8. PubMed ID: 18801058
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Complex karyotype is a marker of very poor prognosis in over 70-year-old patients with acute myeloid leukemia and extended types of myelodysplastic syndrome and high comorbidity index].
    Gritsaev SV; Martynkevich IS; Abdulkadyrov KM; Ivanova MP; Petrova EV; Zapreeva IM; Tiranova SA; Potikhonova NA
    Ter Arkh; 2012; 84(7):16-21. PubMed ID: 23038966
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bone marrow transplantation for myelodysplastic syndrome and secondary leukemia: outcome of 86 patients.
    Sutton L; Leblond V; Le Maignan C; Jouet JP; Kuentz M; Gluckman E; Blaise D; Marit G; Attal M; Troussard X
    Bone Marrow Transplant; 1991; 7 Suppl 2():39. PubMed ID: 1878712
    [No Abstract]   [Full Text] [Related]  

  • 40. Importance of early detection and follow-up of FLT3 mutations in patients with acute myeloid leukemia.
    Colovic N; Tosic N; Aveic S; Djuric M; Milic N; Bumbasirevic V; Colovic M; Pavlovic S
    Ann Hematol; 2007 Oct; 86(10):741-7. PubMed ID: 17579862
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.